Bottom line
Is FRSLX a good fund? The bottom line
FRSLX is the Class A share class of Nuveen Small/Mid Cap Growth Opportunities Fund, a managed mid-cap mutual fund from Nuveen / TIAA.
Annual fees run 1.13% — about $113 a year on every $10,000 invested, more expensive than 72% of mid-cap funds we track.
It returned +1.5% over one year, +0.1% a year over five years, +8.4% a year over ten (as of Dec 31, 2025, per its prospectus).
With $162 million in net assets and 82 holdings, its largest position is Impinj Inc (2.0%) and the top 10 make up 17.7% of the portfolio.
This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.
What to watch
- Expensive for its category (1.13%)
- 5-year return in the bottom quarter of its category
- Front-end sales load up to 5.75%
- 12b-1 marketing fee of 0.25% a year
- High turnover (119% a year) can mean more taxable distributions
Updated Nov 19, 2026
What FRSLX invests in
The investment objective of the Fund is capital appreciation.
Under normal circumstances, the Fund invests at least 80% of the sum of its net assets and the amount of any borrowings for investment purposes in equity securities of small-capitalization and mid-capitalization growth companies. Small-capitalization and mid-capitalization companies are defined as companies that have market capitalizations within the market capitalization range of the companies in the Russell 2500 Index. The market capitalization range is determined based on the companies in the index as of the last business day of the month in which the index was most recently reconstituted and may be updated to reflect any changes to the index composition and the market capitalization of companies in the index. Growth companies are those that are constituents of at least one of the following indexes on the last business day of the month in which its most recent reconstitution was…
From the fund's prospectus (filed Feb 27, 2026).
FRSLX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FRSLX | +1.5% | +0.1% | +8.4% |
| Mid-Cap median | +7.9% | +8.1% | +9.9% |
Source: Fund prospectus, as of Dec 31, 2025
What FRSLX costs
On a $10,000 investment, FRSLX's 1.13% expense ratio costs about $113 a year. The prospectus estimates $1,957 in total costs over 10 years (assuming 5% annual returns). The median mid-cap fund charges 0.88%.
FRSLX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Impinj Inc | 1.96% |
| 2 | FirstCash Holdings Inc | 1.94% |
| 3 | Encompass Health Corp | 1.82% |
| 4 | Guardant Health Inc | 1.79% |
| 5 | Agilysys Inc | 1.78% |
| 6 | Merit Medical Systems Inc | 1.77% |
| 7 | HealthEquity Inc | 1.75% |
| 8 | ATI Inc | 1.63% |
| 9 | Axsome Therapeutics Inc | 1.62% |
| 10 | Applied Industrial Technologies Inc | 1.61% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 17.7% of the fund. See all top 25 holdings and asset mix →